Market Research Logo

Eye Infections Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

Global Eye Infections Therapeutics Market: About this market

Technavio’s eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.

Global Eye Infections Therapeutics Market: Overview

Rising geriatric population

The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.

Growing adoption of generics

The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global eye infections therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global eye infections therapeutics market is highly fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.

Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Conjunctivitis - Market size and forecast 2018-2023
Keratitis - Market size and forecast 2018-2023
Blepharitis - Market size and forecast 2018-2023
Other eye infections - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Rising number of government initiatives
Growing adoption of generics
Saturation in the pipeline landscape
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Akorn Inc.
Allergan Plc
Bausch Health Companies Inc.
Bayer AG
Daiichi Sankyo Co. Ltd.
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.
Sanofi
Santen Pharmaceutical Co. Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Conjunctivitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Conjunctivitis - Year-over-year growth 2019-2023 (%)
Exhibit 22: Keratitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Keratitis - Year-over-year growth 2019-2023 (%)
Exhibit 24: Blepharitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Blepharitis - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other eye infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other eye infections - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Akorn Inc. - Vendor overview
Exhibit 53: Akorn Inc. - Business segments
Exhibit 54: Akorn Inc. - Organizational developments
Exhibit 55: Akorn Inc. - Segment focus
Exhibit 56: Akorn Inc. - Key offerings
Exhibit 57: Akorn Inc. - Key customers
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Product segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Segment focus
Exhibit 62: Allergan Plc - Key offerings
Exhibit 63: Allergan Plc - Key customers
Exhibit 64: Bausch Health Companies Inc. - Vendor overview
Exhibit 65: Bausch Health Companies Inc. - Business segments
Exhibit 66: Bausch Health Companies Inc. - Organizational developments
Exhibit 67: Bausch Health Companies Inc. - Geographic focus
Exhibit 68: Bausch Health Companies Inc. - Segment focus
Exhibit 69: Bausch Health Companies Inc. - Key offerings
Exhibit 70: Bausch Health Companies Inc. - Key customers
Exhibit 71: Bayer AG - Vendor overview
Exhibit 72: Bayer AG - Business segments
Exhibit 73: Bayer AG - Organizational developments
Exhibit 74: Bayer AG - Geographic focus
Exhibit 75: Bayer AG - Segment focus
Exhibit 76: Bayer AG - Key offerings
Exhibit 77: Bayer AG - Key customers
Exhibit 78: Daiichi Sankyo Co. Ltd. - Vendor overview
Exhibit 79: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 80: Daiichi Sankyo Co. Ltd. - Organizational developments
Exhibit 81: Daiichi Sankyo Co. Ltd. - Geographic focus
Exhibit 82: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 83: Daiichi Sankyo Co. Ltd. - Key customers
Exhibit 84: GlaxoSmithKline Plc - Vendor overview
Exhibit 85: GlaxoSmithKline Plc - Business segments
Exhibit 86: GlaxoSmithKline Plc - Organizational developments
Exhibit 87: GlaxoSmithKline Plc - Geographic focus
Exhibit 88: GlaxoSmithKline Plc - Segment focus
Exhibit 89: GlaxoSmithKline Plc - Key offerings
Exhibit 90: GlaxoSmithKline Plc - Key customers
Exhibit 91: Novartis AG - Vendor overview
Exhibit 92: Novartis AG - Business segments
Exhibit 93: Novartis AG - Organizational developments
Exhibit 94: Novartis AG - Geographic focus
Exhibit 95: Novartis AG - Segment focus
Exhibit 96: Novartis AG - Key offerings
Exhibit 97: Novartis AG - Key customers
Exhibit 98: Pfizer Inc. - Vendor overview
Exhibit 99: Pfizer Inc. - Business segments
Exhibit 100: Pfizer Inc. - Organizational developments
Exhibit 101: Pfizer Inc. - Geographic focus
Exhibit 102: Pfizer Inc. - Segment focus
Exhibit 103: Pfizer Inc. - Key offerings
Exhibit 104: Pfizer Inc. - Key customers
Exhibit 105: Sanofi - Vendor overview
Exhibit 106: Sanofi - Business segment
Exhibit 107: Sanofi - Organizational developments
Exhibit 108: Sanofi - Geographic focus
Exhibit 109: Sanofi - Segment focus
Exhibit 110: Sanofi - Key offerings
Exhibit 111: Sanofi - Key customers
Exhibit 112: Santen Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 113: Santen Pharmaceutical Co. Ltd. - Business segments
Exhibit 114: Santen Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 115: Santen Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 116: Santen Pharmaceutical Co. Ltd. - Segment focus
Exhibit 117: Santen Pharmaceutical Co. Ltd. - Key offerings
Exhibit 118: Santen Pharmaceutical Co. Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report